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Objective: Inflammation is likely a major contributor to spinal cord reperfusion injury after aortic reconstruction. Systemic
4-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-cyclohexane-
carboxylic acid methyl ester (ATL-146e), a selective adenosine A2A agonist, has been shown to reduce paralysis after spinal
cord ischemia. We hypothesized that ATL-146e reduces cytokine production during spinal cord reperfusion, curtailing
inflammation and decreasing spinal cord capillary platelet-endothelial cell adhesion molecule–1 (PECAM-1) expression.
Study design: New Zealand White rabbits sustained spinal cord ischemia with 45-minute cross-clamping of the infrarenal
aorta. One group of animals received intravenous ATL-146e at 0.06 g/kg/min for 3 hours during reperfusion,
beginning after 30 minutes of ischemia. A second group received saline solution vehicle alone for 3 hours, serving as an
ischemic control. A third group served as sham-operated animals, undergoing laparotomy with anesthesia. Serum was
assayed with enzyme-linked immunosorbent assay for tumor necrosing factor- (TNF-). Animals were allowed to
recover for 48 hours and were evaluated for hind-limb motor function with the Tarlov (0 to 5) scoring system. At
necropsy, animals from each group yielded spinal cords for immunohistochemical staining for PECAM-1. Data are
expressed as mean  standard error of the mean, with statistical analysis with Student t test and Kruskal-Wallis
nonparametric test.
Results: Markedly improved Tarlov scores were seen in rabbits with ATL-146e (P < .001) during spinal cord reperfusion
as compared with ischemic control animals. A significant reduction was found in TNF- in the sera of rabbits with
ATL-146e infusion (P < .01) as compared with ischemic control animals. Significantly reduced endothelial PECAM-1
staining intensity (P < .05) was seen in microscopic spinal cord sections from rabbits with ATL-146e.
Conclusion: ATL-146e, an adenosine A2A agonist, reduces spinal cord reperfusion injury. The mechanism of the
protection may involve a reduction in circulating TNF- during a critical 3-hour reperfusion interval and reduction in
spinal cord endothelial PECAM-1 upregulation. (J Vasc Surg 2002;35:994-8.)
There are four G protein–coupled adenosine receptor
subtypes, A1, A2A, A2B, and A3R.
1 We have synthesized and
characterized 4-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-di-
hydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-
ynyl}-cyclohexanecarboxylic acid methyl ester (ATL-146e)
as a potent and selective agonist of A2A adenosine recep-
tors.2,3 We recently reported that ATL-146e reduces paral-
ysis in a rabbit model if given during the first 3 hours of
reperfusion after 45 minutes of infrarenal aortic occlusion.4
We also observed an incremental preservation of hind-limb
function (as indicated with improved Tarlov scores) in
treated animals at 48 hours associated with increasing the
duration of intravenous systemic ATL-146e treatment
from 0 to 3 hours. This finding was coupled with histologic
evidence of decreased neuronal damage and reduced neu-
trophil infiltration into the injured spinal cord at the zone
of ischemic injury 48 hours after spinal cord ischemia.4
A2A receptor activation suppresses the release of tumor
necrosing factor–TNF (TNF-) from activated human
monocytes.5 The physiologic significance of reducing
TNF- production was shown by Harada and colleagues6
who reported an in vivo reduction of liver reperfusion
injury in a rat model after systemic infusion of an adenosine
A2A agonist. In their experiment, reduction in liver injury
correlated with a diminution in hepatic levels of TNF-
during reperfusion. ATL-146e has been shown to reduce
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renal reperfusion injury, and this effect is correlated with
reduced expression of P-selectin and intercellular adhesion
molecule–1 on renal vascular endothelial cells.7 On the
basis of these independent observations, we considered the
possibility that reduction in systemic inflammation with
treatment with ATL-146e during spinal cord reperfusion
may prevent early systemic TNF- elaboration, thus reduc-
ing leukocyte extravasation and reducing localized spinal
cord inflammation during the first 48 hours of reperfusion.
The hypothesis of this study is that ATL-146e decreases
spinal cord reperfusion injury, as indicated with Tarlov
neurologic scores, and that this protection is associated
with reduced systemic TNF- release. We also hypothe-
sized a concomitant reduction in spinal cord capillary en-
dothelial activation, manifested by decreased capillary
platelet-endothelial cell adhesion molecule-1 (PECAM-1)
immunostaining in animals treated with ATL-146e during
early spinal cord reperfusion.
MATERIALS AND METHODS
ATL-146e was synthesized, purified, and pharmaco-
logically evaluated on the basis of binding to recombinant
human adenosine A2A receptors as described previously.
2,3
Animal surgery. All animal protocols were reviewed
and approved by the Animal Review Committee of the
University of Virginia. Animals received humane care in
compliance with the “Guide for the Care and Use of
Laboratory Animals” as described by the Institute of Lab-
oratory Animal Resources, Commission on Life Sciences,
National Research Council (Washington: National Acad-
emy Press; 1996). Thirty-six New Zealand rabbits (weight,
3.0 to 3.5 kg) were selected and acclimatized for a mini-
mum of 3 days within our vivarium. Each underwent
anesthesia with an intramuscular injection of xylazine hy-
drochloride (10 mg) and ketamine hydrochloride (100
mg). An ear vein catheter was placed for administration of
additional medications and intravenous fluids. The animals
were intubated, placed supine on a heated operating table,
and ventilated with a mixture of 98% oxygen and 2%
halothane. Core body temperature was carefully main-
tained at 36° C  0.5° C in all animals with a heating
blanket and with closing the abdominal cavity in a timely
fashion during the treatment interval. An ear arterial cath-
eter was placed into a marginal artery for continuous mon-
itoring of arterial pressure. Heparin sodium (2000 units)
was administered intravenously and allowed to circulate for
5 minutes. A midline laparotomy was made, and the viscera
reflected to the right. After opening of the retroperito-
neum, the abdominal aorta and inferior vena cava were
identified. These great vessels were collectively clamped
with Satinsky clamps just distal to the left renal artery and
again proximal to the aortoiliac bifurcation. The technique
of clamping both the aorta and vena cava is described in
earlier experiments in which the venous outflow was used as
a route of retrograde administration of adenosine.8 We
continued this practice in this experiment on the basis of
the reproducibility of creating an ischemic spinal cord
lesion and to avoid hemorrhage associated with dissecting
the vena cava from the adjacent aorta. Each animal underwent
45 minutes of warm spinal cord ischemia, with the clamps
removed just before closure. Pulse oximetry assured ade-
quate oxygenation throughout the procedure.
Drug administration. Eight L of stock ATL-146e
solution (5 g/mL in dimethyl sulfoxide) was diluted in a
4-mL normal saline solution carrier. With a Harvard pump,
the compound (40 g) was infused into an ear vein at a
constant rate for 3 hours, beginning after 30 minutes of
spinal cord ischemia. Control ischemic animals were given
carrier (4 mL normal saline solution) without drug. One
group of animals (A2A, n  16) received 0.06 g/kg/min
intravenous ATL-146e, infused over 3 hours, beginning
after 30 minutes of ischemic time, and a second cohort
(I/R, n  16) received vehicle and served as a control
group. A third group (sham, n 4) underwent laparotomy
with general anesthesia alone and served as shams.
Physiologic testing. After surgery, the animals were
supported with food and fresh water. At 48 hours after
surgery, hind-limb neurologic function was evaluated with
the following modified Tarlov scoring system8: 0, atony; 1,
slight movement; 2, sits with assistance; 3, sits alone; 4,
weak hop; 5, normal gait/hopping. The same technician in
a blinded fashion performed all neurologic functional eval-
uations. Survival of animals was limited to 48 hours in
accordance with our agreement with the Animal Review
Committee at the University of Virginia.
Enzyme-linked immunosorbent assay measurement
of serum tumor necrosing factor-. One mL of blood
was sampled from the marginal ear artery of each rabbit
(n 4 per group) at the start of the operation, on release of
the aortic cross clamp, and every hour until the termination
of the 3-hour reperfusion treatment interval. The whole
blood was allowed to coagulate on ice, and the serum
fraction was separated with centrifugation at 7000 rpm for
5 minutes. Ninety-six well plates (Nunc Maxisorb, Ro-
chester, NY) were coated with phosphate-buffered saline
solution (PBS) diluted 2 g/mL purified capture anti–
TNF- antibody (BD Pharmingen International, San Di-
ego, Calif) overnight at 4° C. Serum samples were diluted
1:4 in PBS and incubated in the plates overnight at 4° C.
Biotinylated detection antibody (BD Pharmingen Interna-
tional) was diluted in 2 g/mL PBS and added to the 96
well plates. Streptavidin-horseradish peroxidase conjugate
(Pierce Corporation, Rockford, Ill) was added to the wells,
and color reaction was established with tetramethylbenzi-
dine substrate system for enzyme-linked immunosorbent
assay (Sigma Chemical Corporation, St Louis, Mo). The
optical density at 450 nm for each well was measured with
a microplate reader (Dynex Technologies, Waltham,
Mass). The optical densities for each sample were compared
with the standard TNF- concentration curve (25 to 2000
g/mL; R2 0.96 and 0.89) to quantitate serum TNF-.
Platelet-endothelial cell adhesion molecule–1 stain-
ing. At necropsy, lumbar sections of spinal cord from the
ischemic zone of injury (26 cm from prominens) in A2A
(n 5), I/R (n 5), and sham (n 3) animals were fixed
in 10% formalin and paraffin embedded for sectioning. The
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selection of specimens was on the basis of the availability of
spinal cord tissues from each animal, some of which were
frozen in liquid nitrogen for alternative assays and unavail-
able for histologic analysis. Every effort was made to keep
the selection random and representative of the experimen-
tal cohort. Two-m thick sections were affixed to glass
slides, deparaffinized in xylene, and rehydrated in serial
dilutions of ethanol. Antigen retrieval was conducted with
a microwave-heated unmasking solution (Vector Labora-
tories, Inc, Burlingame, Calif). After blocking, the sample
sections were incubated with a 1:200 dilution of polyclonal
goat PECAM-1 antibody (Santa Cruz Biotechnology,
Santa Cruz, Calif) overnight at 4° C. After washing in PBS,
sections were incubated with biotinylated horse antigoat
antibody (Vector Laboratories, Inc) for 1 hour at room
temperature. Immunostaining was accomplished with a
horseradish peroxidase system (Vector Laboratories, Inc)
and diaminobenzidinechomogen (DAKO Corporation,
Carpinteria, Calif). Counterstaining was performed with
filtered hematoxylin. Four high-power (400) fields were
examined for all sections and graded for endothelial stain-
ing intensity in a blinded fashion by the two independent
trained observers (0, no staining in any field; 1, light
staining in some fields; 2, less than 50% staining of capillar-
ies in all fields; 3, greater than 50% staining in all fields; and
4, intense staining of all capillaries observed). The final
scoring grades from each observer were averaged to com-
pare treatment groups.
Statistical analysis. All results are expressed as the
mean  standard error of the mean. Tarlov scores and
TNF- levels were analyzed for between-group differences
with Student t test. The relative PECAM-1 staining inten-
sity was compared between groups with Kruskal-Wallis
nonparametric test. Significance was defined as a P value
less than .05, as determined with SPSS Software (SPSS Inc,
Chicago, Ill).
RESULTS
Operative outcome. Sixteen A2A rabbits, 15 I/R, and
four sham-operated animals survived the procedure. Ade-
quate urine output was maintained throughout the opera-
tive period. No difference was seen in hemodynamic pa-
rameters between experimental and control groups.
Euthermia was maintained within all groups. One control
rabbit died early during recovery and was excluded from
further analysis.
Neurologic outcome. Tarlov scores of I/R rabbits
averaged 0.75  0.35, indicating dense lower extremity
paralysis 48 hours after ischemia. In contrast, Tarlov scores
of A2A rabbits averaged 4.1 0.25, indicating significantly
improved hind-limb motor function compared with I/R
(P  .001; Fig 1). Sham-operated animals showed normal
hind-limb motor function.
Serum tumor necrosing factor–measurement. No
detectable TNF- was found before 2 hours reperfusion in
A2A or I/R groups, and peak levels were observed at 2
hours after cross-clamp removal in all groups (Fig 2). A
significant reduction was seen in peak TNF- in the sera in
A2A (238  71 pg/mL; P  .001) compared with I/R
animals (3748  1258 pg/mL). Sham-operated animals
showed widely varied levels of plasma TNF- (2167 
1922 pg/mL). By 3 hours after removal of the cross clamp,
there was almost no detectible serum TNF- in A2A rabbits
(32 31g/mL; P .01). However, elevated TNF-was
seen in both sham-operated (1436  1152 g/mL) and
I/R (1423 184 g/mL) groups. Despite the differences
noted between mean TNF- levels in sham-operated and
A2A groups, the variation was not significantly different at
2-hour or 3-hour time points (P  .42 and P  .34).
Platelet-endothelial cell adhesion molecule–1 stain-
ing. Lumbar spinal cord capillary endothelial PECAM-1
expression was assayed 48 hours after surgery via immuno-
histochemistry as a marker for endothelial cell activation.
PECAM-1 staining was observed in all groups (Fig 3). On
reviewers’ blinded analysis of light microscopy, markedly
Fig 1. Tarlov scores in ischemic control subjects (I/R), animals
with ATL-146e (A2A), and sham-operated animals 48 hours after
spinal cord ischemia (*P  .001). Significant difference was seen
between A2A and sham-operated groups, indicating incomplete
recovery of hind-limb motor function after treatment with ATL-
146e (P  .002).
Fig 2. Comparison of systemic TNF- (pg/mL) levels between
sham-operated rabbits and rabbits with 45-minute spinal cord
ischemia without (I/R) and with (A2A) systemic ATL-146e pro-
tection at 1.0, 2.0, and 3.0 hours after aortic cross-clamp release
(*P  .01). Sham-operated animals did not show significantly
different systemic TNF- levels compared with either I/R or A2A
animals at any timepoint.
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increased PECAM-1 staining was seen in spinal cord sec-
tions from I/R animals (3.2  0.37) compared with A2A
animals (1.6  0.4) and sham-operated animals (1.3 
0.67; P .05; Fig 3). No difference in PECAM-1 staining
was observed between A2A and sham-operated animals
(P  .46). The Tarlov scores for I/R (1.0  0.31), A2A
(4.2 0.37), and sham (5.0 0.0) animals from which the
tissues were obtained were not significantly different from
the Tarlov scores from the respective groups and were
believed to be representative without selection bias.
DISCUSSION
Clamping of the thoracic aorta has been shown to
reduce spinal blood flow in a variety of animal models, and
this effect has been documented in humans as well.9 The
precise mechanisms by which low blood flow induces per-
manent injury are not well understood, and most current
techniques of protection are directed at reducing injury
that occurs during ischemia rather than secondary injury
that occurs during reperfusion. The results of this study and
of prior experiments with the rabbit model suggest that a
significant portion of injury after spinal cord ischemia oc-
curs during reperfusion. In this study, we observed that
ATL-146e substantially reduces systemic TNF- early after
spinal cord ischemia/reperfusion. We previously described
a dose-response curve of concentration of ATL-146e given
and the correlating Tarlov score for animals treated for the
first 3 hours of reperfusion after 45 minutes of spinal cord
ischemia. We reported that, at a concentration of 0.06
g/kg/min, neurologic functional outcome was opti-
mized and a concentration of 0.22 g/kg/min was asso-
ciated with cardiovascular collapse and death of animal
subjects. We attributed this observation to loss of A2A
receptor specificity at high doses, with attendant hemody-
namic instability caused by nonspecific adenosine receptor
activation.4
Although we showed a significant reduction in systemic
TNF- in A2A rabbits compared with I/R animals, it is
difficult to extricate the effect of laparotomy alone on
systemic TNF- levels because sham-operated animals
showed a wide range of serum TNF- levels in spite of the
absence of aortic clamping. A closed technique of balloon
occlusion of the aorta may initiate an ischemia/reperfusion
injury without the concomitant tissue injury of dissection
and visceral exposure that can cause early nonspecific rises
in TNF-. Also of concern is the relationship between
TNF- concentration and extremity or visceral ischemia
after temporary exclusion of the hind-limb vessels and
inferior mesenteric artery during the cross-clamp interval.
The causal relationship between TNF- concentration,
spinal cord capillary endothelial activation, and neurologic
injury could be strengthened if the same observations held
true for cerebrospinal fluid TNF- levels or for local tissue
levels assayed with alternative techniques. The conclusion
that systemic TNF- reduction results in spinal cord pro-
tection from reperfusion inflammation requires the as-
sumption that plasma measurements accurately reflect the
cellular environment at the zone of ischemic injury.
The ability of leukocytes to traverse the vascular wall in
response to inflammation depends in part on the expression
of adhesion molecules on the vascular endothelium. Endo-
thelial cells treated with cytokines show upregulation of
adhesion molecules and local elaboration of other factors
integral to the coagulation cascade. Induction of the vas-
cular endothelium to an activated state occurs in multiple
disease states and is initiated by varied mechanisms. Multi-
ple experiments in vascular wall biology support a causal
relation between both acute and chronic increases in
plasma TNF- and endothelial activation in systemic dis-
ease, in which unchecked endothelial activation can exac-
erbate end-organ injury.10-12
PECAM-1 is a constitutively expressed adhesion mol-
ecule found on capillary endothelium that regulates platelet
adhesion and transendothelial migration of leukocytes. Be-
cause of this basal endothelial PECAM-1 expression, it is
available at the time of ischemia injury stimulus and may
play a role in the early inflammatory processes elicited with
I/R. A recent study exploring reperfusion injury of rat
Fig 3. Representative photomicrograph (400) shows staining for PECAM-1 in rabbit lumbar spinal cord section
taken (A) 48 hours after sham laparotomy, (B) 48 hours after 45-minute spinal cord I/R, and (C) 48 hours after
45-minute spinal cord I/R with systemic ATL-146e during reperfusion.
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cremasteric muscle revealed that inhibiting endothelial
PECAM-1 activity decreases diapedesis of leukocytes into
surrounding tissues after 24 hours of reperfusion.13 A
similar finding was made in a rabbit model for myocardial
reperfusion injury in which inhibition of PECAM-1 re-
duced infarct size measured 2 hours after coronary occlu-
sion.14
Schnell and colleagues15 have found that ischemia and
reperfusion of the central nervous system result in an exag-
gerated increase in PECAM-1, intercellular adhesion mol-
ecule–1, and vascular cell adhesion molecule–1 in the spinal
cord after mechanical injury and that the presence of these
adhesion molecules is closely associated with breakdown of
the blood brain barrier within 24 hours. In a separate
experiment, administration of TNF- resulted in acute
disruption of the blood brain barrier in the spinal cord,
leukocyte infiltration, and inflammatory destruction of spi-
nal cord architecture.15 On the basis of these findings, we
sought to elucidate whether PECAM-1 is expressed above
constitutive levels after spinal cord ischemia and reperfu-
sion in the rabbit. We found that not only is PECAM-1
expression increased with spinal cord ischemia/reperfu-
sion, but that this effect can be blunted by the administra-
tion of ATL-146e administered early during the reperfu-
sion period. Furthermore, this effect is correlated with an
early reduction in serum TNF- levels and durable protec-
tion of hind-limb motor function at 48 hours.
ATL-146e possibly exerts at least two independent
effects on PECAM-1 expression. The first mechanism in-
volves reduction in systemic TNF-, with secondary reduc-
tion in spinal cord capillary PECAM-1 upregulation. An
alternative mechanism may be attributed to the direct effect
of ATL-146e on endothelial A2A receptors that contributes
to the down regulation of the endothelial PECAM-1 re-
sponse to injury.
Our experimental findings indicate that key events in
the initiation of spinal cord ischemia/reperfusion injury
may occur at an early, predictable interval during reperfu-
sion after spinal cord ischemia. ATL-146e given systemi-
cally to circulating blood reduces serum TNF-, endothe-
lial PECAM-1, and neurologic impairment. The efficacy of
3-hour ATL-146e infusion coincides with peak serum
TNF- levels observed 2 hours after untreated spinal cord
ischemia/reperfusion. Treatment of spinal cord ischemia/
reperfusion with agonists of A2A adenosine receptors, such
as ATL-146e, may be clinically useful to reduce spinal cord
inflammatory insult after thoracic aortic surgery.
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